Earlier this year, the Centers for Medicare and Medicaid Services scrapped a previous proposal, from the Biden administration ...

The company expects that the U.S. COVID-19 vaccination rate will be “maybe a couple of points lower” than the prior level of ...

The pivotal Phase II trial is testing Allogene’s CAR T candidate cemacabtagene ansegedleucel for large B-cell lymphoma.

Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...

Strengthening strategic partnerships and expanding client base through North America-Asia manufacturing hubs ■  Targeting ...

After decades of limited progress—owing to the difficulty of treating the disease and resultant market risk—glioblastoma ...

A ripple effect of the NIH's slashed 2026 budget will be felt throughout the biopharma ecosystem. Young companies must act ...